CN105125532A - Medicament oxaliplatin composition for treating cancers - Google Patents

Medicament oxaliplatin composition for treating cancers Download PDF

Info

Publication number
CN105125532A
CN105125532A CN201510629398.XA CN201510629398A CN105125532A CN 105125532 A CN105125532 A CN 105125532A CN 201510629398 A CN201510629398 A CN 201510629398A CN 105125532 A CN105125532 A CN 105125532A
Authority
CN
China
Prior art keywords
oxaliplatin
weight portion
crystal
medicine
combination thing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201510629398.XA
Other languages
Chinese (zh)
Inventor
卢德国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Huazhicao Medical Technology Co Ltd
Original Assignee
Qingdao Huazhicao Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Huazhicao Medical Technology Co Ltd filed Critical Qingdao Huazhicao Medical Technology Co Ltd
Priority to CN201510629398.XA priority Critical patent/CN105125532A/en
Publication of CN105125532A publication Critical patent/CN105125532A/en
Withdrawn legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a medicament oxaliplatin composition for treating cancers, belonging to the technical field of medicaments. The composition is prepared from oxaliplatin and anhydrous sodium carbonate; the oxaliplatin is crystals, and an X-ray powder diffraction pattern obtained by measurement with Cu-Ka rays is as shown in Figure 1. The novel crystal form of the oxaliplatin provided by the invention is different from a crystal form structure of the prior art. Experiments prove and find that the novel crystal form compound is high in purity, good in flowability, good in stability, low in impurity content, unlikely to absorb moisture, and safe and reliable in clinical application; a powder injection prepared from the novel crystal form compound is good in stability after matching with a solvent, extremely low in content of insoluble particles and very suitable for clinical application.

Description

A kind of medicine oxaliplatin combination thing of Therapeutic cancer
Technical field
The invention belongs to medical art, relate to a kind of medicine oxaliplatin combination thing of Therapeutic cancer.
Background technology
Oxaliplatin is the third generation platinum-containing anticancer drug after cisplatin, carboplatin, all has broad-spectrum anti-tumor activity in vivo and in vitro, also has cytotoxicity to the tumor cell of resistance to cisplatin.In vivo with in vitro study, all can be observed the synergistic cytotoxicity of oxaliplatin and 5-fluorouracil use in conjunction.Oxaliplatin untoward reaction is few, there is not the Toxicity of Kidney of cisplatin, the bone marrow depression of carboplatin is not had yet, its Main Function position is DNA, by forming conjugate with DNA, stop it to copy and transcribe, reach the object of killing tumor cell, and anti-tumor activity spectrum, to colorectal cancer, nonsmall-cell lung cancer, gastric cancer, ovarian cancer to various kinds of cell tumor, especially there is significant inhibitory action to the tumor cell of resistance to carboplatin, cisplatin, be used for the treatment of the patient of the transfer of the colon cancer after fluorouracil Endodontic failure, can use by fluorouracil alone or in combination.
At present, oxaliplatin as the first-line treatment medicinal application of metastatic colorectal carcinoma in clinical.When being used as treatment, oxaliplatin is with intravenous form administration.Intravenous injection is that one absorbs without human gastrointestinal tract, directly by the administering mode of infusion of medicine blood of human body, if contain from the impurity produced in raw material or production process in the preparation of injection, these impurity directly will enter blood circulation of human body without gastrointestinal tract barrier, and these impurity, even quantity is extremely small also may cause great infringement to human body.Because compound chemical change can occur in storage process as oxidation, decompose, impurity will be accumulated along with the prolongation of medicine storage time, determines that the principal element of Oxaliplatin for Injection effect duration is also the growth of total impurities in storage process.
The stability of oxaliplatin in water is all poor, and its aqueous solution can be degraded and be produced oxalic acid, two water DACH platinum, two water DACH platinum dimers and platinum class impurity.Its mesoxalic acid has toxicity because of itself, is one of impurity clearly controlled in European Pharmacopoeia oxaliplatin crude drug standard, within 2010, also has control in the first enlarged edition standard regulation to oxalic acid: must not exceed 0.20% of oxaliplatin labelled amount at Chinese Pharmacopoeia.Therefore, in finished product, the minute differences of moisture also can produce significant impact to effect duration of product, the residual moisture in finished product be chemical change provide reaction medium.
In the quality standard of existing product, total impurities is an important index, therefore, strict requirement is had to total impurities in drug quality, the national drug standards (the WS1-(X-090)-2003Z of such as State Food and Drug Administration) in related substance is limited to " summation of each impurity peak area must not be greater than 1.0% of the peak area at reference substance solution main constituent peak ".(standard No.: JX20020117) regulation " total amount of impurity must not cross 1.0% of oxaliplatin labelled amount " in import drugs registered standard.
Meanwhile, oxaliplatin wettability power is comparatively strong, and especially after preparing injectable powder, wettability power grow, mobility is deteriorated, and the easy moisture absorption goes bad and occurs content uniformity.If the amount of oxaliplatin impurity, moisture therefore can be controlled well, will effectively improve the quality of product, reduce the generation of side effect, make medication safer; Also will improve the stability of medicine simultaneously, extend the effect duration of product, thus reduce selling cost.
The present inventor starts with from the research of oxaliplatin solid chemical material existence, through a large amount of experimental studies, obtain a kind of oxaliplatin crystalline compounds being different from prior art, pass through verification experimental verification, find that this crystal compound purity is high, good fluidity, good stability, impurity content is low, not easily moisture absorption, clinical practice is safe and reliable, utilize the injectable powder that this crystal compound is obtained, good stability, good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
In prior art, for the crystal formation of oxaliplatin, had many research, but the hygroscopicity of impurity content, stability and crystal formation is still undesirable, brings difficulty also to while have impact on self stability the preparation of preparation.
The present invention, through a large amount of experimental studies, has obtained a kind of oxaliplatin crystalline compounds being different from prior art, has passed through verification experimental verification, find that this crystal compound purity is high, good fluidity, good stability, impurity content is low, not easily moisture absorption, clinical practice is safe and reliable, utilizes the injectable powder that this crystal compound is obtained, good stability, good with solvent compatibility rear stability, particulate matter content is extremely low, is very suitable for clinical practice.
Summary of the invention
Goal of the invention of the present invention is the medicine oxaliplatin combination thing providing a kind of Therapeutic cancer.
In order to complete object of the present invention, the technical scheme of employing is:
The medicine oxaliplatin combination thing of a kind of Therapeutic cancer of the present invention, consisting of of described compositions: oxaliplatin 1 weight portion, natrium carbonicum calcinatum 0.1-0.3 weight portion; Described oxaliplatin is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
First optimal technical scheme of the present invention is consisting of of described compositions: oxaliplatin 1 weight portion, natrium carbonicum calcinatum 0.15-0.25 weight portion.
Second optimal technical scheme of the present invention is consisting of of described compositions: oxaliplatin 1 weight portion, natrium carbonicum calcinatum 0.2 weight portion.
3rd optimal technical scheme of the present invention is the dosage form of described compositions is injection, and the preparation method of described injection comprises the following steps:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
The preparation method of the oxaliplatin crystal in the present composition comprises the following steps:
Be in the mixed solvent of the methanol of 6 times of oxaliplatin weight, N-methylacetamide in 35 DEG C of volumes by oxaliplatinum, the volume ratio of methanol and N-methylacetamide is 1.5:5; First add with the speed of 40ml/min the ethanol of 9 times and the mixed solvent of ether that volume is oxaliplatin weight, the volume ratio of ethanol, ether is 1:3, and limit edged stirs, control temperature 35 DEG C, growing the grain 3h; And then the chloroform of 7 times that volume total amount is oxaliplatin weight is added with the speed of 20ml/min, after growing the grain 1h, be cooled to-5 DEG C with the speed of 10 DEG C/h, then keep mixing speed 90r/min stirring and crystallizing, growing the grain 3h; Filter, washing, drying under reduced pressure obtains oxaliplatin crystalline compounds.
The polymorphism of solid chemical is the natural phenomena that a kind of general material exists, this phenomenon refers to that a kind of solid chemical can exist 2 kinds or two or more crystal form state, be also called the polymorphic state of material, the polymorphic state of material is also referred to as " allomorphism " phenomenon.Although its chemical nature of allomorphous solid matter is identical, its physicochemical property may be different.For " allomorphism medicine " that physicochemical property is different, also can show the curative effect of different disease preventing and treating clinically, directly affect application and the clinical effectiveness of medicine.
Accompanying drawing explanation
Fig. 1 is the X-ray powder diffraction that the oxaliplatin crystal of the embodiment of the present invention 1 preparation uses the measurement of Cu-K alpha ray to obtain.
Detailed description of the invention
Below by specific embodiment, summary of the invention of the present invention is described in further detail, but does not therefore limit content of the present invention.
embodiment 1:the preparation of oxaliplatin crystal
Be in the mixed solvent of the methanol of 6 times of oxaliplatin weight, N-methylacetamide in 35 DEG C of volumes by oxaliplatinum, the volume ratio of methanol and N-methylacetamide is 1.5:5; First add with the speed of 40ml/min the ethanol of 9 times and the mixed solvent of ether that volume is oxaliplatin weight, the volume ratio of ethanol, ether is 1:3, and limit edged stirs, control temperature 35 DEG C, growing the grain 3h; And then the chloroform of 7 times that volume total amount is oxaliplatin weight is added with the speed of 20ml/min, after growing the grain 1h, be cooled to-5 DEG C with the speed of 10 DEG C/h, then keep mixing speed 90r/min stirring and crystallizing, growing the grain 3h; Filter, washing, drying under reduced pressure obtains oxaliplatin crystalline compounds.
As shown in Figure 1, its purity of high-performance liquid chromatogram determination is 99.8% to the X-ray powder diffraction pattern that the oxaliplatin crystal prepared uses the measurement of Cu-K alpha ray to obtain.
embodiment 2:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.1 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 3:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.15 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 4:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.2 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 5:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.25 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
embodiment 6:the preparation of oxaliplatin combination thing
Consist of: oxaliplatin crystal 1 weight portion prepared by the present invention, natrium carbonicum calcinatum 0.3 weight portion.
Preparation method is:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
test example 1: draw moist test
It is moist that this test example has investigated drawing of oxaliplatin compound crystal provided by the invention, and this experiment is drawn moist test direction principle according to Chinese Pharmacopoeia 2010 editions second annex Ⅺ Ⅹ J medicine and carried out, and the results are shown in Table 1.
Table 1 draws moist result of the test
Wherein, sample 1 is embodiment 1 product;
Sample 2 is embodiment 2 products;
Sample 3 is embodiment 3 products;
Sample 4 is the Oxaliplatin crystal compound prepared with reference to patent CN102643308B embodiment 1;
Sample 5 is the Oxaliplatin crystal compound prepared with reference to patent CN100372858C embodiment;
Sample 6 is commercially available oxaliplatin crude drug, originates from Jiangsu Aosaikang Pharmaceutical Co., Ltd..
As seen from Table 1, compared with the Oxaliplatin crystal compound of prior art, oxaliplatin hydrate crystal of the present invention to draw wet percentage weight increase little, hygroscopicity is little.
Also carried out above-mentioned test to oxaliplatin compound prepared by other embodiment of the present invention, the result of acquisition is similar.
test example 2: fluidity test
This experimental example has investigated the mobility of oxaliplatin compound crystal provided by the invention.
This experimental example by working sample angle of repose assess sample mobility, concrete grammar is as follows: sample thief granule, flow into from fixing little funnel in circular surface plate, know and obtain the highest cone, measure cone height H and radius R, calculate α angle of repose by tan α=H/R, the results are shown in Table 2, angle of repose is larger, and mobility is poorer.
Table 2 fluidity test result
Wherein, sample 1-3 is 3 batches of products that embodiment 1 obtains;
Sample 4 is the Oxaliplatin crystal compound prepared with reference to patent CN102643308B embodiment 1;
Sample 5 is the Oxaliplatin crystal compound prepared with reference to patent CN100372858C embodiment;
Sample 6 is commercially available oxaliplatin crude drug, originates from Jiangsu Aosaikang Pharmaceutical Co., Ltd..
As seen from Table 2, compared with the Oxaliplatin crystal compound of prior art, oxaliplatin compound crystal of the present invention has excellent mobility, is conducive to the accuracy improving subpackage, and is easy to mix homogeneously when mixing with other compositions.
experimental example 3: solubility detection experiment
Concrete operations: get test sample 1, add water for injection 10ml, start writing time immediately, slowly rotate (0.5-1 circle/second, 2 seconds, interval), when content dissolves completely, record dwell time, should not have visible insoluble matter; Separately get 5 test sample repetitive operations, it's 3 minutes must not past average dissolution time (n=6); The dissolution time often propping up test sample must not cross 3 times of average dissolution time.Press official method simultaneously and detect visible foreign matters and particulate matter.By embodiment 2,3,4, commercially available contrast 1,2 detects as stated above, result is as following table 3.
Table 3 solubility detection experiment result
Reach a conclusion according to upper table: product of the present invention is obviously better than commercially available prod in redissolution time, visible foreign matters and particulate matter index.
experimental example 4: long term test
Sample thief, by commercially available back, place under long term test (temperature 25 DEG C ± 2 DEG C, relative humidity 65% ± 5%) condition after 4 years, detect moisture, impurity content, result is as following table 4.
Table 4 is three batch sample assays after 4 years
As can be seen from Table 4, the embodiment of the present invention 2,3,4 product is after temperature 25 ± 2 DEG C, relative humidity 65 ± 5% place 4 years, and impurity and moisture content index are obviously better than commercially available and prior art products, and stability is better.
Similar test is carried out to other embodiments, has obtained similar result of the test.
Above-mentioned test shows that the compound of novel crystal forms structure of the present invention has the hygroscopicity and higher stability significantly improved, compared with prior art component is simple for the injectable powder prepared of this oxaliplatin crystal compound, good stability, moisture, impurity content are low, solubility is good, and particulate matter number is few.

Claims (5)

1. a medicine oxaliplatin combination thing for Therapeutic cancer, is characterized in that, consisting of of described compositions: oxaliplatin 1 weight portion, natrium carbonicum calcinatum 0.1-0.3 weight portion; Described oxaliplatin is crystal, and the X-ray powder diffraction pattern that the measurement of use Cu-K alpha ray obtains as shown in Figure 1.
2. the medicine oxaliplatin combination thing of Therapeutic cancer according to claim 1, is characterized in that, consisting of of described compositions: oxaliplatin 1 weight portion, natrium carbonicum calcinatum 0.15-0.25 weight portion.
3. the medicine oxaliplatin combination thing of Therapeutic cancer according to claim 2, is characterized in that, consisting of of described compositions: oxaliplatin 1 weight portion, natrium carbonicum calcinatum 0.2 weight portion.
4., according to the medicine oxaliplatin combination thing of the arbitrary described Therapeutic cancer of claim 1-3, it is characterized in that, the dosage form of described compositions is injection, and the preparation method of described injection comprises the following steps:
(1) take oxaliplatin crystal and natrium carbonicum calcinatum in proportion, fully mix;
(2) to divide in the cillin bottle after being filled to sterilizing and to jump a queue.
5. the medicine oxaliplatin combination thing of Therapeutic cancer according to claim 1, is characterized in that, the crystal preparation method of described oxaliplatin is:
Be in the mixed solvent of the methanol of 6 times of oxaliplatin weight, N-methylacetamide in 35 DEG C of volumes by oxaliplatinum, the volume ratio of methanol and N-methylacetamide is 1.5:5; First add with the speed of 40ml/min the ethanol of 9 times and the mixed solvent of ether that volume is oxaliplatin weight, the volume ratio of ethanol, ether is 1:3, and limit edged stirs, control temperature 35 DEG C, growing the grain 3h; And then the chloroform of 7 times that volume total amount is oxaliplatin weight is added with the speed of 20ml/min, after growing the grain 1h, be cooled to-5 DEG C with the speed of 10 DEG C/h, then keep mixing speed 90r/min stirring and crystallizing, growing the grain 3h; Filter, washing, drying under reduced pressure obtains oxaliplatin crystalline compounds.
CN201510629398.XA 2015-09-29 2015-09-29 Medicament oxaliplatin composition for treating cancers Withdrawn CN105125532A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510629398.XA CN105125532A (en) 2015-09-29 2015-09-29 Medicament oxaliplatin composition for treating cancers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510629398.XA CN105125532A (en) 2015-09-29 2015-09-29 Medicament oxaliplatin composition for treating cancers

Publications (1)

Publication Number Publication Date
CN105125532A true CN105125532A (en) 2015-12-09

Family

ID=54711356

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510629398.XA Withdrawn CN105125532A (en) 2015-09-29 2015-09-29 Medicament oxaliplatin composition for treating cancers

Country Status (1)

Country Link
CN (1) CN105125532A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055324A (en) * 2015-09-23 2015-11-18 青岛华之草医药科技有限公司 Platinum anticancer oxaliplatin composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055324A (en) * 2015-09-23 2015-11-18 青岛华之草医药科技有限公司 Platinum anticancer oxaliplatin composition

Similar Documents

Publication Publication Date Title
CN101389343B (en) Doxorubicin formulations for anti-cancer use
WO2006047931A1 (en) The use of dipyridamole in manufacturing the anti-malignant tumor medicines
CN102617584B (en) Irinotecan hydrochloride compound and medicinal composition thereof
CN105125532A (en) Medicament oxaliplatin composition for treating cancers
CN104523674B (en) A kind of composition for injection using oxaliplatin as main ingredient composition
CN103980279B (en) A kind of methotrexate compound and methotrexate for injection
EP2934593B1 (en) Cabazitaxel composition
CN105055324A (en) Platinum anticancer oxaliplatin composition
CN103073617B (en) N-(2)-L-alanyl-L-glutamine compound
CN101507747B (en) Preparation method of astragalus total-saponin sodium chloride injector
CN104814949B (en) Improve chlorogenic acid acylate and the application of chlorogenic acid bioavilability
CN105078953A (en) Anticancer oxaliplatin composition
CN105250317A (en) Antitumor drug oxaliplatin composition
CN102727867B (en) Antineoplastic pharmaceutical composition and application thereof, kit and package
AU2016311704B2 (en) Use of dihydroxyacetone in preparation of anti-cancer medicaments
CN105055308A (en) Platinum-based antitumor drug oxaliplatin composition liquid injection
CN104945443A (en) Drug, namely oxaliplatin compound, for treating cancer
CN105055347A (en) Oxaliplatin composition freeze-dried powder injection for treating metastatic colorectal cancers
CN104829653B (en) A kind of oxaliplatin hydrate crystal and lyophilized injectable powder thereof
CN102727429B (en) Pidotimod injection with modified stability, and preparation method thereof
CN104940151A (en) Oxaliplatin freeze-dried powder injection composition as anti-cancer drug
CN101559037A (en) Binary solution type preparation for intravenous injection and intracerebral injection
CN105380951A (en) Platinum pharmaceutic preparation as well as preparation method and application thereof
CN103357021A (en) Pharmaceutical composition using albumin as pharmaceutical carrier
CN104013951A (en) Nitric oxide donor type glutathione compound injection and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20151209

WW01 Invention patent application withdrawn after publication